Truist Securities Maintains Hold on Organogenesis Holdings, Lowers Price Target to $2

Benzinga Newsdesk www.benzinga.com Negative 71.5%

Neg 71.5% Neu 0% Pos 0%

Truist Securities analyst Ravi Misra maintains Organogenesis Holdings (NASDAQ:ORGO) with a Hold and lowers the price target from $3 to $2.